Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Endometrial cancer ILLUMINATED
Introducing JEMPERLI (dostarlimab), the first licensed monotherapy immunotherapy for recurrent/advanced dMMR/MSI-H endometrial cancer1
JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.1
Want to discover more about how JEMPERLI can support your patients?
Footnotes
dMMR, mismatch repair deficient; EC, endometrial cancer; MSI-H, microsatellite instability-high.
References
- JEMPERLI (dostarlimab) Summary of Product Characteristics.
Adverse events should be reported.
Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/ (UK) or search for MHRA Yellow Card in the Google Play or Apple App store.
Adverse events should also be reported to GSK Limited on 0800 221 441 or uksafety@gsk.com
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
July 2022 ӏ PM-GB-DST-WCNT-220001 (V2.0)
